Reviva Pharmaceuticals announced it expects FDA feedback in Q4 2026 on a new formulation of brilaroxazine for its RECOVER-2 Phase 3 trial targeting schizophrenia. The company plans to start a bioequivalence study in Q1 2027 and begin patient enrollment in the first half of 2027, pending additional financing. Reviva also secured priority examination for a patent that could extend protection of this formulation through 2046. The company reported a Q3 2026 net loss of $2.3 million but increased cash reserves to $17.5 million, focusing on advancing brilaroxazine as a differentiated treatment option.
Reviva Pharmaceuticals' recent financial results provide context for readers following health sector stocks. As of Nov 13, 2026 06:01 WIB, 26 of 150 priced health-sector US stocks on Pluang rose while 122 fell. Notable movers include Recursion Pharmaceuticals Inc (RXRX) at USD 3.35 with a -6.69% change, Moderna, Inc. (MRNA) at USD 232.70 with a -6.43% change, and Erasca Inc. (ERAS) at USD 15.72 with a -6.43% change.
Atlas Energy Corp. completed its first royalty acquisition for $15 million on producing oil and gas assets in Southwest Alberta, funded by cash. The company began generating royalty revenue immediately, earning $141,000 in just seven days post-acquis...
AELO Swiss Academy has transformed into an international airline pilot training organization with bases in Locarno, Lugano, and Cuneo, reflecting over 40 years of aviation heritage. The academy reported a 186% increase in operations in September 2026...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Liberty Defense Holdings Ltd. has engaged Global Impact Advisors LLC to enhance its investor relations, strategic communications, and capital markets advisory services. The partnership aims to boost institutional investor awareness, strengthen shareh...
